Đang chuẩn bị liên kết để tải về tài liệu:
A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Concurrent chemotherapy and radiation is the standard treatment for unresectable stage III Lung adenocarcinoma. However, no optimal concurrent chemotherapeutic regimen has been described. This study aimed to assess concurrent pemetrexed, nedaplatin and thoracic intensity-modulated radiotherapy followed by consolidation pemetrexed/nedaplatin for unresectable Stage IIIA/B lung adenocarcinoma. |

TÀI LIỆU LIÊN QUAN

Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: Study protocol

A prospective phase I study of hypofractionated neoadjuvant radiotherapy for locally advanced gastric cancer

BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: A first-inhuman phase-I study

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma

Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease smallcell lung cancer (LD-SCLC): TORG 0604

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

Optimal biological dose: A systematic review in cancer phase I clinical trials

Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: Study protocol

A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer